UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000009746 |
|---|---|
| Receipt number | R000011422 |
| Scientific Title | The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer |
| Date of disclosure of the study information | 2013/01/10 |
| Last modified on | 2016/04/11 16:05:04 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer
Acronym
The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer
Scientific Title
The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer
Scientific Title:Acronym
The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer
Region
| Japan |
Condition
Condition
Lung cancer
Classification by specialty
| Pneumology | Hematology and clinical oncology | Chest surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate immunological effects of combined cell-based immunotherapy in patients with treatments-refractory lung cancer
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Phase II
Assessment
Primary outcomes
Immunological monitoring
Key secondary outcomes
Anti-tumor effect
Disease-free survival
Overall survival
Safety
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Vaccine |
Interventions/Control_1
Dendritic cell-based vaccine (day 1)+
LAK immunotherapy (day 1)
Q2weeks, 6 cycles
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 85 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1. Histologically determined lung cancer
2. Histologically determined highly expression of MUC1 in cancer cells
3. Refractory for standard anti-cancer treatments
4. Aged 20-85 years old
5. ECOG performance status 0-2
6. No prior anti-cancer treatments within 4 weeks
7. Adequate organs function
8. Written informed consent
Key exclusion criteria
1) Severe complications
(i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infarction within 6 months, liver cirrhosis, uncontrolled diabetes, hemorrhagic tendency )
2) Active infections
3) Active simultaneous cancer
4)Massive pleural or pericardial effusion
5) Concurrent treatment with steroids or immunosuppressing agent
6) Other conditions not suitable for this study
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Koji Teramoto |
Organization
Shiga University of Medical Science
Division name
Department of Clinical Oncology
Zip code
Address
Seta-Tsukinowa, Otsu, Shiga, Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Koji Teramoto |
Organization
Shiga University of Medical Science
Division name
Department of Clinical Oncology
Zip code
Address
Seta-Tsukinowa, Otsu, Shiga, Japan
TEL
Homepage URL
Sponsor or person
Institute
Shiga University of Medical Science
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 01 | Month | 10 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 07 | Month | 21 | Day |
Date of IRB
Anticipated trial start date
| 2011 | Year | 08 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 01 | Month | 10 | Day |
Last modified on
| 2016 | Year | 04 | Month | 11 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011422
